NCT00146029TerminatedNot Applicable
Companion Pharmacogenetic Study to UMCC 9900/9901
University of Michigan Rogel Cancer Center1 site in 1 countryStarted: September 5, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Locations
- 1
Study Overview
Brief Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Study Design
- Study Type
- Observational
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who participated on UMCC 9900/9901
- •Living patients must give written informed consent
Exclusion Criteria
- •No tumor block tissue available
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic SyndromeMetabolic SyndromeBreast CancerNCT06261918Fondazione Policlinico Universitario Agostino Gemelli IRCCS120
Completed
Not Applicable
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant ChemotherapyBreast CancerNCT00911911Centre Oscar Lambret66
Completed
Not Applicable
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to ChemotherapyBreast NeoplasmsNeoplasm MetastasisNCT01198301Peking University Cancer Hospital & Institute42
Recruiting
Not Applicable
Pharmacogenetic analysis to investigate the association between efficacy and neurotoxicity of oxaliplatin and single nucleotide polymorphismsColorectal cancerJPRN-UMIN000002490Kyoto University Hospital133
Active, not recruiting
Phase 2
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic SettingBreast CancerNCT02546232Oslo University Hospital196